Dr. Yutao Liu 刘雨桃
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Immunotherapy, chemotherapy, and targeted therapy for lung cancer, pleural mesothelioma, thymoma, and other thoracic tumors.
Dr. Liu holds a doctorate in oncology. The doctor focuses on comprehensive and individualized treatment for common tumors. Dr. Liu has extensive clinical experience in chemotherapy and targeted therapy for thoracic tumors, with a particular focus on immunotherapy, chemotherapy, and targeted therapy for lung cancer.
Name order: in Chinese the family name comes first (Liu Yutao). Papers usually list the name as Yutao Liu or Liu Y.
Selected publications
83 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- PLOS Digit Health, 2026 (first author): ITHindex: An integrated web-based platform for intratumor heterogeneity evaluation. PubMed 42664234
- Signal Transduct Target Ther, 2026 (first author): Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. PubMed 42660909
- Int J Cancer, 2026 (senior author): Immune checkpoint inhibitors combined with anti-angiogenic therapy as second- or further-line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers. PubMed 40888203
- Int Immunopharmacol, 2025 (senior author): Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials. PubMed 39826454
- Cell Biosci, 2024 (senior author): Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer. PubMed 39267195
- Cancer Cell Int, 2024 (senior author): Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. PubMed 38622705
- Front Immunol, 2023 (senior author): Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer. PubMed 37795095
- Clin Transl Med, 2023 (first author): IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers. PubMed 37649319
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion